A 10-Year Study on Antihypertensive Drug Use Based on Prescription Data in Bohsei Pharmacy
10.3820/jjpe1996.1.107
- VernacularTitle:望星薬局における薬歴データを利用した降圧薬の使用実態研究
- Author:
Kazuo SAMIZO
;
Chikuma HAMADA
;
Chiyoji ISHIKURA
;
Tadashi KUSUNOKI
- Publication Type:Journal Article
- Keywords:
drug utilization;
pharmacy record;
prescription data;
antihypertensive drugs
- From:Japanese Journal of Pharmacoepidemiology
1996;1(2):107-115
- CountryJapan
- Language:Japanese
-
Abstract:
Objective : To examine antihypertensive drug use in major therapeutic categories and to compare with guidelines for antihypertensive therapy.
Design : Cross-sectional drug utilization survey.
Methods : Prescription data on antihypertensives, from 1985 to 1994, were extracted from electronic record accumulated in Bohsei Pharmacy. Repeated prescriptions were identified by patients' identification code. Patients using diuretics (DU), beta-blockers (BB), Ca-channel blockers (CCB), ACE-inhibitors (ACEI), and others were counted in each calender year. These data were compared with 1993 annual utilization data of antihypertensive drugs in Western countries obtained from a commercial database.
Results : The use of CCB and ACEI increased to reach a high proportion of 43.0 % and 18.7 %, respectively, in 1994. On the other hand, the use of DU and BB showed a marked decrease and DU accounted for 16.3 %, BB for 13.5 % in 1994. The other categories were minor. These figures from Bohsei Pharmacy formed a contrast to those in Western countries. For instance, the use of DU waspredominant in the UK. In the US and Germany, CCB was widely used (≅30%) but DU was also used to a similar extent (30-40%).
Conclusion : The pattern of antihypertensive drug use found in the record of Bohsei Pharmacy may be judged to be appropriate since the JNC and other guidelines recommend DU, BB, CCB, and ACEI as the first line drugs. However, the proportion of the use of CCB is an issue of concern and might be criticized to be too high in light of the fact mentioned by those guidelines that efficacy/safety of CCB's has not yet been proven sufficiently based on morbidity and mortality data.
